These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24462908)

  • 1. Therapeutic vaccines against hepatitis C virus.
    Xue J; Zhu H; Chen Z
    Infect Genet Evol; 2014 Mar; 22():120-9. PubMed ID: 24462908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods to Evaluate Novel Hepatitis C Virus Vaccines.
    Ahlén G; Frelin L
    Methods Mol Biol; 2016; 1403():221-44. PubMed ID: 27076133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination against chronic hepatitis C virus infection.
    Ip PP; Nijman HW; Wilschut J; Daemen T
    Antiviral Res; 2012 Oct; 96(1):36-50. PubMed ID: 22841700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.
    Zhang S; Bakshi RK; Suneetha PV; Fytili P; Antunes DA; Vieira GF; Jacobs R; Klade CS; Manns MP; Kraft AR; Wedemeyer H; Schlaphoff V; Cornberg M
    J Virol; 2015 Aug; 89(16):8304-17. PubMed ID: 26041301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2011 Dec; 21(12):1811-30. PubMed ID: 22022980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hepatitis C virus protein epitopes for vaccine development.
    Koshy R; Inchauspé G
    Trends Biotechnol; 1996 Oct; 14(10):364-9. PubMed ID: 8987634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys.
    Park SH; Lee SR; Hyun BH; Kim BM; Sung YC
    Vaccine; 2008 Jul; 26(32):3978-83. PubMed ID: 18556097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of vaccines for hepatitis C virus infection.
    Ghasemi F; Rostami S; Meshkat Z
    World J Gastroenterol; 2015 Nov; 21(42):11984-2002. PubMed ID: 26576087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The development of therapeutic vaccine for hepatitis C virus].
    Kimura K; Kohara M
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1451-7. PubMed ID: 23064054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice.
    Takei S; Omoto C; Kitagawa K; Morishita N; Katayama T; Shigemura K; Fujisawa M; Kawabata M; Hotta H; Shirakawa T
    Vaccine; 2014 May; 32(25):3066-74. PubMed ID: 24657718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
    Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
    J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccine expressing the non-structural proteins of hepatitis C virus diminishes the expression of HCV proteins in a mouse model.
    Wada T; Kohara M; Yasutomi Y
    Vaccine; 2013 Dec; 31(50):5968-74. PubMed ID: 24144476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
    Smyk-Pearson S; Tester IA; Lezotte D; Sasaki AW; Lewinsohn DM; Rosen HR
    J Infect Dis; 2006 Aug; 194(4):454-63. PubMed ID: 16845628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune and non-immune responses to hepatitis C virus infection.
    Sun J; Rajsbaum R; Yi M
    World J Gastroenterol; 2015 Oct; 21(38):10739-48. PubMed ID: 26478666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
    Feinstone SM; Hu DJ; Major ME
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
    Puig M; Mihalik K; Tilton JC; Williams O; Merchlinsky M; Connors M; Feinstone SM; Major ME
    Hepatology; 2006 Sep; 44(3):736-45. PubMed ID: 16941702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Success and failure of virus-specific T cell responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Dig Dis; 2011; 29(4):416-22. PubMed ID: 21894013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.